SAPIEN 3 versus Myval transcatheter heart valves for transcatheter aortic valve implantation (COMPARE-TAVI 1): a multicentre, randomised, non-inferiority trial

Heart, Artery and Coronary DiseasesTherapy and Intervention

A Randomized Comparison of the Treatment Sequence of Percutaneous Coronary Intervention and Transcatheter Aortic Valve Implantation: Rationale and Design of the TAVI PCI Trial

Am Heart J

Stähli BE, Linke A, Westermann D, Van Mieghem NM, Leistner DM, Massberg S, Alber H, Mügge A, Musumeci G, Kesterke R, Schneider S, Kastrati A, Ford I, Ruschitzka F, Kasel MA, TAVI PCI Investigators

doi: 10.1016/j.ahj.2024.07.019

Heart, Artery and Coronary DiseasesTherapy and Intervention

Transcatheter Aortic Valve Implantation in Low-Risk Tricuspid or Bicuspid Aortic Stenosis: The NOTION-2 Trial

Eur Heart J

Jørgensen TH, Thyregod HGH, Savontaus M, Willemen Y, Bleie Ø, Tang M, Niemela M, Angerås O, Gudmundsdóttir IJ, Sartipy U, Dagnegaard H, Laine M, Rück A, Piuhola J, Petursson P, Christiansen EH, Malmberg M, Olsen PS, Haaverstad R, Sondergaard L, De Backer O, NOTION-2 investigators

doi: 10.1093/eurheartj/ehae331

Heart, Artery and Coronary DiseasesTherapy and Intervention

Transcatheter Aortic Valve Implantation by Valve Type in Women With Small Annuli: Results From the SMART Randomized Clinical Trial

JAMA Cardiol

Tchétché D, Mehran R, Blackman DJ, Khalil RF, Möllmann H, Abdel-Wahab M, Ben Ali W, Mahoney PD, Ruge H, Bleiziffer S, Lin L, Szerlip M, Grubb KJ, Byku I, Guerrero M, Gillam LD, Petronio AS, Attizzani GF, Batchelor WB, Gada H, Rogers T, Rovin JD, Whisenant B, Benton S, Gardner B, Padang R, Althouse AD, Herrmann HC

doi: 10.1001/jamacardio.2024.3241

Thrombosis and Stroke

Plain versus drug balloon and stenting in severe ischaemia of the leg (BASIL-3): open label, three arm, randomised, multicentre, phase 3 trial

BMJ

Bradbury AW, Hall JA, Popplewell MA, Meecham L, Bate GR, Kelly L, Deeks JJ, Moakes CA, BASIL-3 Investigators

doi: 10.1136/bmj-2024-080881

Heart Failure

Early integration of palliative care versus standard cardiac care for patients with heart failure (EPCHF): a multicentre, parallel, two-arm, open-label, randomised controlled trial

Lancet Healthy Longev

Balata M, Radbruch L, Hesse M, Westenfeld R, Neukirchen M, Pfister R, Batzler YN, Öztürk C, Kavsur R, Tiyerili V, Weltermann B, Pölsler R, Standl T, Nickenig G, Becher MU, Heart Failure Network Rhineland

doi: 10.1016/j.lanhl.2024.08.006

Heart, Artery and Coronary DiseasesTherapy and Intervention

Trends in Transcatheter Versus Surgical Aortic Valve Replacement Outcomes in Patients With Low-Surgical Risk: A Systematic Review and Meta-Analysis of Randomized Trials

J Am Heart Assoc

Kazemian S, Fallahtafti P, Sharifi M, Mohammadi NSH, Soleimani H, Moghadam AS, Karimi E, Sattar Y, Jenab Y, Mehrani M, Hajizeinali A, Iskander M, Sabet MF, Salehi N, Al-Azizi K, Hakim D, Alam M, Hosseini K

doi: 10.1161/JAHA.124.036179

Heart, Artery and Coronary DiseasesTherapy and Intervention

Safety and feasibility of early discharge after transcatheter aortic valve implantation with ACURATE Neo-the POLESTAR trial

Clin Res Cardiol

Ooms JF, Cornelis K, Wijeysundera HC, Vandeloo B, Van Der Heyden J, Kovac J, Wood D, Chan A, Wykyrzykowska J, Rosseel L, Cunnington M, van der Kley F, Rensing B, Voskuil M, Hildick-Smith D, Van Mieghem NM

doi: 10.1007/s00392-024-02436-z

Cardiovascular Risk and DiseasesTherapy and Intervention

Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial

Lancet

Choi KH, Park YH, Lee JY, Jeong JO, Kim CJ, Yun KH, Lee HC, Chang K, Park MW, Bae JW, Doh JH, Cho BR, Kim HY, Kim W, Kim U, Rha SW, Hong YJ, Lee HJ, Ahn SG, Kim DI, Cho JH, Her SH, Jeon DS, Han SH, Lee JB, Lee CW, Kang D, Lee JM, Park TK, Yang JH, Lee SY, Choi SH, Gwon HC, Song YB, Hahn JY, SMART-CHOICE 3 investigators

doi: 10.1016/S0140-6736(25)00449-0

Heart, Artery and Coronary Diseases

Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up of a multicentre, open-label, randomised trial

Lancet

Fearon WF, Zimmermann FM, Ding VY, Takahashi K, Piroth Z, van Straten AHM, Szekely L, Davidavičius G, Kalinauskas G, Mansour S, Kharbanda R, Östlund-Papadogeorgos N, Aminian A, Oldroyd KG, Al-Attar N, Jagic N, Dambrink JE, Kala P, Angerås O, MacCarthy P, Wendler O, Casselman F, Witt N, Mavromatis K, Miner SES, Sarma J, Engstrøm T, Christiansen EH, Tonino PAL, Reardon MJ, Otsuki H, Kobayashi Y, Hlatky MA, Mahaffey KW, Desai M, Woo YJ, Yeung AC, Pijls NHJ, De Bruyne B

doi: 10.1016/S0140-6736(25)00505-7

Related content

A Randomized Comparison of the Treatment Sequence of Percutaneous Coronary Intervention and Transcatheter Aortic Valve Implantation: Rationale and Design of the TAVI PCI Trial

Transcatheter Aortic Valve Implantation in Low-Risk Tricuspid or Bicuspid Aortic Stenosis: The NOTION-2 Trial

Transcatheter Aortic Valve Implantation by Valve Type in Women With Small Annuli: Results From the SMART Randomized Clinical Trial

Plain versus drug balloon and stenting in severe ischaemia of the leg (BASIL-3): open label, three arm, randomised, multicentre, phase 3 trial

Early integration of palliative care versus standard cardiac care for patients with heart failure (EPCHF): a multicentre, parallel, two-arm, open-label, randomised controlled trial

Trends in Transcatheter Versus Surgical Aortic Valve Replacement Outcomes in Patients With Low-Surgical Risk: A Systematic Review and Meta-Analysis of Randomized Trials

Safety and feasibility of early discharge after transcatheter aortic valve implantation with ACURATE Neo-the POLESTAR trial

Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial

Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up of a multicentre, open-label, randomised trial